Specifications Table {#s0005}
====================

TableSubject areaBiologyMore specific subject areaMolecular biology, VirologyType of dataGraph, FigureHow data was acquiredCell culture, Real-time PCR, Luciferase assay, CAT-ELISAData formatAnalyzedExperimental factorsHuman monocyte-derived macrophages and cell lines containing integrated copies of the HIV-1 promoter; HIV-1 infection; treatment with TLR3 ligands, and pharmacological inhibitorsExperimental featuresReal-time PCR, luciferase assay, and chloramphenicol acetyltransferase assayData source locationUniversity of Nebraska Medical Center, Omaha, USAData accessibilityData are with this article

Value of the data {#s0010}
=================

•The approach used in this data article allows for the prediction of biological pathways involved in receptor--ligand interactions.•Data on the mechanistic basis of TLR3-HIV interactions would be useful to others investigating viral transactivation and replication.•Others interested in studying the functional effects of receptor--ligand interactions could learn from our approach.•This approach would be of interest when determining the critical role of time on gene transcription and expression.

1. Data {#s0015}
=======

To determine whether the TLR3 ligand polyinosinic-polycytidylic acid (PIC) can interact with HIV-1 to affect gene transcriptional regulation in human monocyte-derived macrophages (MDM), time-dependent and concentration-dependent real-time PCR analyses were performed on uninfected or HIV-1 infected human MDM treated with PIC. Genes analyzed included the pro-inflammatory cytokine IL-6 and transcription factors known to regulate the HIV-1 promoter activity (STAT-1, REL-B, JUN, CEBPA, and CEBPG). To investigate the role and involvement of these transcription factors in TRL3-mediated HIV-1 transactivation, pharmacological inhibitors targeting their signaling pathways were used, with and without TLR3 ligands, in luciferase and chloramphenicol acetyltransferase (CAT) ELISA assays on TZM-bl and U38 cells, both of which contained integrated copies of the HIV-1 promoter.

2. Experimental design, materials and methods {#s0020}
---------------------------------------------

### 2.1. HIV-1 infection of MDM and real-time PCR {#s0025}

Human MDM were obtained from freshly elutriated human monocytes as previously described [@bib1], [@bib2], cultured in 6-well plates (2 million cells per well), and treated with 10 or 25 μg/ml PIC for 2--120 h, with each experimental condition performed in triplicate. In separate experiments, MDM were infected with HIV-1~ADA~ at a multiplicity of infection of 0.01 as previously described [@bib1], [@bib2], [@bib3], [@bib4], with or without PIC treatment (10 and 25 µg/ml) for 2--120 h, with each experimental condition performed in triplicate. Following treatment, cells were harvested, total RNA was extracted using the Trizol reagent, and real-time PCR performed as described in the main manuscript [@bib1]. All PCR reagents, probes and primers were from Applied Biosystems and primers IDs were as follows: CEBPA (Hs00269972_s1), CEBPG (Hs01922818_s1), JUN (Hs99999141_s1), STAT1 (Hs00234829_m1), RELB (Hs00232399_m1), IL-6 (Hs00985639), and GAPDH (Hs99999905_m1). For each gene and each sample, data was normalized to the sample's GAPDH to quantify the effects of PIC (10 and 25 μg/ml) on IL-6, STAT-1, REL-B, JUN, CEBPA, and CEBPG mRNA in uninfected ([Fig. 1](#f0005){ref-type="fig"}) and HIV-1-infected ([Fig. 2](#f0010){ref-type="fig"}) human MDM.

### 2.2. Luciferase and chloramphenicol acetyltransferase (CAT) assays {#s0030}

TZM-bl and U38 cells were treated for 48 h with PIC (25 or 50 µg/ml), with or without the inhibitor of NFκB transcriptional activation (481406, 20 nM), the JNK inhibitor ( 420119, 10 µM), the inhibitor of c-Jun/JNK complex (420130, 5 µM), and the MEKK7/MKK7 inhibitor (5ZO, 5 µM). Each experimental condition was performed in triplicate and following treatment, cells were harvested, washed with phosphate-buffered saline, and lysed as described [@bib1]. Cell lysates were then used to quantify the luciferase activity ([Fig. 3](#f0015){ref-type="fig"}A) and the CAT activity ([Fig. 3](#f0015){ref-type="fig"}B) in each sample using the Luciferase Assay System (Promega, Madison, WI) and the CAT ELISA kit (Roche Diagnostics Indianapolis, IN), as described in the main manuscript [@bib1].

In separate experiments, cells were treated for 48 h with PIC (25 µg/ml), with or without the AP-1 inhibitor (SR11302, 2 µM and 10 µM), the JNK inhibitor V (420129, 10 µM and 20 µM), and the IRAK-1/4 inhibitor (5 µM and 10 µM). Each experimental condition was performed in triplicate and following treatment, the effects of PIC and inhibitors on HIV-1 transactivation was quantified in TZM-bl cells ([Fig. 4](#f0020){ref-type="fig"}A) or U38 cells ([Fig. 4](#f0020){ref-type="fig"}B). The main manuscript [@bib1] includes the manufacturer׳s names, catalog numbers, and mechanisms of action of each inhibitor.

Appendix A. Supplementary material {#s0040}
==================================

Supplementary material
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Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2015.12.022](http://dx.doi.org/10.1016/j.dib.2015.12.022){#ir0011}.

![Real-time PCR quantification of JUN (A), STAT1 (B), RELB (C), IL-6 (D), CEBPA (E), and CEBPG (F) mRNA in untreated and human macrophages treated with the TLR3 ligand PIC. For both MDM treated with 10 μg/ml and 25 μg/ml PIC, \**P*\<0.05, ∞*P*\<0.001. ∝*P*\<0.001, \#*P*\<0.0001, compared to untreated MDM.](gr1){#f0005}

![Real-time PCR quantification of JUN (A), STAT1 (B), RELB (C), IL-6 (D), CEBPA (E), and CEBPG (F) mRNA in HIV-1-infected human macrophages, untreated or treated with the TLR3 ligand PIC. \**P*\<0.05, ∞*P*\<0.001. ∝*P*\<0.001, \#*P*\<0.0001. *P*-values of infected MDM (HIV-1) are in comparison to non-infected controls (MDM), and *P*-values of infected MDM treated with PIC (HIV-1+PIC(10 μg/ml), and HIV-1+PIC(25 μg/ml)) are in comparison to infected MDM.](gr2){#f0010}

![Quantification of HIV-1 transactivation in TZM-bl (A) and U38 (B) cells treated with TLR3 ligands, with or without the inhibitor of NFκB transcriptional activation ( 481406), the JNK inhibitor ( 420119), the inhibitor of c-Jun/JNK complex ( 420130), and the MEKK7/MKK7 inhibitor (5ZO). \*\*\**P*\<0.001; *P*-values for inhibitors-treated samples are in comparison to the HIV-1 promoter activity in PIC-treated cells.](gr3){#f0015}

![Quantification of HIV-1 transactivation in TZM-bl (A) and U38 (B) cells treated with TLR3 ligands, with or without the inhibitor of AP-1 transcriptional activity (SR11302), the ATP-competitive inhibitor of JNK (420129), and the IRAK1/4 inhibitor \*\*\**P*\<0.001; *P*-values for inhibitors-treated samples are in comparison to the HIV-1 promoter activity in PIC-treated cells.](gr4){#f0020}
